Researchers found that chemotherapy triggers an inflammatory cascade recruiting immune cells to protect the tumor, leading to chemoresistance. Blocking this pathway with existing drugs may restore chemotherapy sensitivity.
A phase 2 trial found that avatrombopag was safe and effective in managing persistent chemotherapy-induced thrombocytopenia, a common complication from cancer treatment. The oral drug helped 70% of patients with low platelet counts stay on their chemotherapy schedule, compared to 17% receiving placebo.
A new drug candidate, IHMT-15137, has been discovered to target key proteins involved in chemotherapy resistance. The compound blocks BMX activity, disrupting downstream signals and reducing E2F1 levels, making cancer cells more sensitive to treatment.
Researchers have identified immune markers that can help doctors determine which breast cancer patients are unlikely to benefit from chemotherapy. The new AI-based method analyzes the body's own immune cells found near a tumor, providing additional insight to identify patients who can safely have chemotherapy withheld.
A recent study published in Science Direct found that patients with detectable circulating tumor DNA (ctDNA) benefit from chemotherapy, with a three-year relapse-free survival rate of 77 percent. The test can help identify patients who require more targeted treatment, potentially reducing the risk of recurrence.
Researchers at The Wistar Institute and Temple University have identified a metabolic target that can help overcome chemotherapy resistance in ovarian cancer. Elevated alpha-ketoglutarate activates an enzyme called TMLHE, which drives carnitine production and loosens the DNA-histone complex, allowing cells to access and fix damaged DNA.
A new study found that chemotherapy can unintentionally reshape the immune system, allowing cancer to persist. Researchers discovered that a standard chemotherapy triggers pyroptosis, releasing inflammatory signals that inhibit tumor treatment.
Immunotherapy combining checkpoint inhibitors, CAR-T, CAR-NK, and cancer vaccines shows promising results in treating AML. Chemotherapy can enhance the efficacy of these treatments by reshaping the tumor microenvironment.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
Researchers developed an AI model that analyzes routine pathology slides to predict breast cancer recurrence and chemotherapy benefit. The model was validated in a large clinical trial and demonstrates fast, accessible, and globally scalable diagnostic capabilities.
A randomized crossover pilot study found that pre-chemotherapy exercise can reduce cancer-related fatigue and attenuate symptoms. High-intensity interval exercise performed before treatment showed significant benefits on Day 5 post-chemotherapy.
A phase 3 clinical trial found romiplostim significantly reduced chemotherapy dose delays and improved platelet counts in patients with gastrointestinal cancers who developed persistent low platelet counts during treatment. The therapy enables patients to maintain chemotherapy intensity, potentially preserving the integrity of cancer c...
Researchers found that patients who followed an exercise prescription while receiving chemotherapy reported fewer problems with thinking and memory and felt less mentally tired. The study suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks.
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.
Research by Queen Mary University of London led to changes in NHS guidelines, allowing hundreds of people with advanced bladder cancer to receive fewer chemotherapy cycles. This results in reduced toxic side effects and a better quality of life during treatment.
A study led by researchers from the Germans Trias i Pujol Research Institute has identified PARG as a new target to enhance chemotherapy in colorectal cancer. Inhibition of PARG significantly increases the cytotoxic effect of chemotherapy, leading to enhanced cell death and apoptosis in different colorectal cancer models.
Research reveals that chemotherapy alters the gut microbiota, producing indole-3-propionic acid, which travels to the bone marrow and rewires immune cell production. This leads to a metastasis-refractory state in preclinical models and improved survival outcomes in patients with colorectal cancer.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
ICIs combined with chemotherapy shows promise for treating EGFR-TKI-resistant NSCLC, improving PFS and OS. Acceptable safety profile for ICIs-chemotherapy regimen, suggesting potential as therapeutic option.
A new study found that a chemo-free combination treatment outperformed targeted therapy and chemotherapy in patients with Ph+ acute lymphoblastic leukemia, achieving higher rates of event-free survival and complete remission. Researchers recommend this approach as the new standard of care for this patient group.
The azacitidine-venetoclax combination significantly improves event-free survival and overall response rates compared to intensive chemotherapy. Patients in the aza-ven arm also experience lower symptom burdens, reduced depression, and improved quality of life.
A clinical trial found a nearly 40% increase in overall survival for glioblastoma patients treated with focused ultrasound and chemotherapy. The study also showed that liquid biopsy tests can detect cancer biomarkers, which are closely concordant with patient outcomes.
Researchers discover IRE1α pathway in immune cells triggers inflammation and nerve damage after chemotherapy, providing a potential target for prevention and treatment. Biomarkers may help identify patients at risk of developing chemotherapy-induced peripheral neuropathy.
A new modeling framework elucidates how antigen heterogeneity, immune selection, and chemotherapy jointly determine tumor evolution and therapeutic outcomes. Chemotherapy reduces antigen heterogeneity, improving the immune microenvironment and enhancing overall treatment efficacy.
A new study from the University of South Australia found that up to 50% of patients are missing out on vital foot care after chemotherapy, despite irreversible nerve damage being a common side effect. Podiatry services can prevent falls, ulcerations, pain, and improve mobility in cancer survivors with CIPN.
Researchers at Mayo Clinic identified a genetic factor contributing to severe liver damage after chemotherapy for colorectal cancer patients. A specific gene variant, PNPLA3, was linked to increased risk of liver injury.
The global Phase 3 HARMONi trial found that ivonescimab plus chemotherapy significantly prolonged progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Median PFS was 6.8 months, and the overall response rate was higher in the ivonescimab group.
The FLAURA2 trial shows osimertinib plus chemotherapy significantly improves overall survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC. The combination also demonstrates a manageable safety profile, extending survival for these patients.
The COMPEL trial demonstrates that patients with EGFR-mutated advanced non-small cell lung cancer benefit from continued osimertinib treatment in combination with platinum-based chemotherapy. This approach is associated with improved progression-free survival and overall survival compared to placebo plus chemotherapy.
Forskolin, a natural compound, significantly improves treatment outcomes for KMT2A-r AML by directly stopping leukaemia cell growth and enhancing chemotherapy effectiveness. Forskolin blocks P-glycoprotein 1, allowing more chemotherapy drugs to enter leukaemia cells, making treatments more potent.
Cancer cells with abundant circular DNA elements (ecDNA) carrying oncogenes like MYCN are resistant to chemotherapy. Combining standard chemotherapy with a secondary therapy targeting these senescent cells leads to improved outcomes in mouse models of neuroblastoma and medulloblastoma.
A groundbreaking cancer drug, KCL-HO-1i, has shown promise in making chemotherapy-resistant cancers more responsive to therapy by targeting a key defence mechanism used by tumours. In preclinical models, the drug has already demonstrated effectiveness in laboratory tests using mouse models of breast cancer.
A study published in JCO Precision Oncology found that genetic testing can significantly improve patient safety by providing tailored doses of chemotherapy, reducing severe side effects. The test identifies variants in two genes that impact how the body processes chemotherapy drugs, allowing doctors to adjust doses and minimize harm.
A CCNY research team found chemotherapy disrupts gene regulation in brain regions linked to decision-making and executive function. This may explain long-term cognitive issues experienced by some cancer patients after treatment.
Chemotherapy-induced pyroptosis in bladder cancer can actually make the disease more resistant to treatment by fueling cancer stem cells. Blocking this inflammatory process with belnacasan may overcome chemoresistance in preclinical models.
Researchers analyzed blood cell genomes from 23 patients treated with various chemotherapies, discovering new patterns of DNA damage and mutational signatures associated with specific drugs. The study suggests using genomic data to choose chemotherapies that minimize premature ageing and potential secondary cancer risks.
Researchers have developed a test that can predict chemotherapy resistance in cancer patients, based on chromosomal instability signatures. This test has the potential to personalize treatment and reduce side effects for patients.
A five-year analysis of the CheckMate-816 clinical trial shows that immunotherapy plus chemotherapy before lung cancer surgery significantly improves long-term survival. Patients who achieved complete remission had a 95% five-year survival rate.
A new study found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer resulted in a 50% reduction in cancer recurrence and death compared to chemotherapy alone. The treatment combination showed significant benefits for patients with deficient DNA mismatch repair genetic makeup.
Researchers at UCSF found that certain gut bacteria can reduce chemotherapy side effects by clearing excess drugs and producing the protective vitamin K2. Patients with more beneficial bacteria had fewer side effects, suggesting that probiotics may help mitigate chemotherapy's impact.
A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers. In a trial where cancers were treated with chemotherapy followed by a targeted cancer drug before surgery, 100% of patients survived the critical three-year period post-surgery.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
A new study suggests that multi-strain probiotics can alleviate chemotherapy-related side effects such as fatigue, nausea, and weakness. Probiotics have been shown to improve blood urea nitrogen levels and enable patients to perform daily activities more independently.
A phase 1 clinical trial led by City of Hope demonstrated the safety and early efficacy of targeted chemotherapy using PIPAC combined with systemic chemotherapy for patients with colorectal and appendiceal cancer that has spread to the peritoneum of the abdominal cavity. The study showed promising results, including histologic, laparos...
Researchers at NUS have developed a non-invasive method to improve chemotherapy effectiveness while reducing side effects. By applying brief magnetic pulses, they demonstrated significant increase in doxorubicin uptake into breast cancer cells.
A study found that adding anthracyclines to taxane-based chemotherapy improved survival outcomes for HR-positive, HER2-negative breast cancer patients with high risk of recurrence. The OncotypeDX genomic test helped identify which patients could benefit from the addition.
A randomized phase 2 clinical trial shows that adding high-dose, intravenous vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months. Patients also experience improved quality of life with reduced side effects.
New treatment combinations and predictive biomarkers hold promise for improving bladder cancer outcomes. The NIAGARA trial showed that combining immune checkpoint inhibitors with chemotherapy can significantly increase two-year survival rates and reduce cancer recurrences.
A clinical trial shows promise in using a gene signature to tailor chemotherapy for high-risk breast cancer patients, improving disease-free survival rates. Patients classified as low risk had significantly higher rates of disease-free and overall survival compared to those at high risk.
Women who started an aerobic exercise program during chemotherapy reported improved cognitive function and quality of life compared to those receiving standard care. The study found that while cognitive performance was similar after chemotherapy completion, the exercise program had a positive impact on self-reported cognitive function.
A study published in JAMA Network Open found that body mass index (BMI) has a more complex relationship with mortality risk during cancer therapy than previously thought. For patients with advanced non-small cell lung cancer, higher BMI was associated with lower mortality when undergoing immunotherapy or conventional chemotherapy. Howe...
A clinical trial by the ECOG-ACRIN Cancer Research Group shows striking results from chemotherapy before surgery to shrink tumors and reduce tissue removal. Patients who received chemotherapy had a 50% chance of preserving vital organs, compared to 15% for those having surgery.
A new AI algorithm assesses immune cells in early-stage bowel cancer tumours to predict recurrence risk. The CD3 Score test has been shown to reliably identify high-risk cancers that are more likely to recur within five years of surgery, enabling clinicians to make informed decisions about chemotherapy treatment.
Tumors with mutations in ERCC2, ATM, or RB1 genes were more likely to be eliminated by cisplatin-based chemotherapy. The study found a correlation between these gene mutations and complete pathologic response to neoadjuvant chemotherapy.
Researchers found that epalrestat increased sensitivity of non-small cell lung cancer tumors to chemotherapy, making it more effective. The study used patient-derived tumor organoids and found that overexpression of AKR1B10 was linked to drug resistance.
A new study has identified specific RNAs that may help identify stage II colon cancer patients who are likely to benefit from chemotherapy following surgery. The researchers found that certain housekeeping RNAs were up-regulated in patients with recurrence, suggesting their potential role in the metastatic process.
Scientists at Stanford University discovered that pancreatic cancer cells become resistant to chemotherapy due to stiff tissue and high hyaluronic acid levels. By altering the matrix, they found it possible to make cancer cells sensitive to chemotherapy again.
A study by Ohio State University researchers found that chemotherapy disrupts the gut microbiome in breast cancer patients, leading to cognitive decline and increased inflammation. The research suggests that targeting the gut microbiome may improve behavioral side effects of chemotherapy.
A new study published in JAMA Oncology found that chemotherapy before surgery can improve survival rates for patients with pancreatic ductal adenocarcinoma (PDAC), an aggressive form of the disease. The modified FOLFIRINOX regimen was administered to 46 patients, resulting in a 67% 12-month progression-free survival rate and a 59% two-...
A UCLA-led study reveals that chemotherapy for early-stage breast cancer in women over 65 can lead to a significant decline in physical function. The study found that 30% of older women who received chemotherapy experienced a substantial decline, with climbing stairs and walking being the most affected activities.